VNDA Stock: Vanda Pharmaceuticals Inc. Stock Price, Analysis & Insights
Get live vnda stock price $5.35, comprehensive Vanda Pharmaceuticals Inc. stock analysis, charts, news, and expert forecast. Real-time vnda stock data and investment insights.
Loading chart...
Company Overview
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Company Information
- CEO
- Mihael H. Polymeropoulos
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 368
Contact Information
- Website
- https://www.vandapharma.com
- Address
- 2200 Pennsylvania Avenue NW
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.71) may provide portfolio stability
Business Model & Strategy
Vanda Pharmaceuticals Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Mihael H. Polymeropoulos, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Vanda Pharmaceuticals Inc. competes in the Biotechnology within the broader Healthcare. With 316.1 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Market, Vanda Pharmaceuticals Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Vanda Pharmaceuticals Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Vanda Pharmaceuticals Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Vanda Pharmaceuticals Inc.
- ⚠Investors should consider how Vanda Pharmaceuticals Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
316.15M
P/E Ratio
-3.72
Beta
0.71
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 316.15M market capitalization
- Trading Volume: 5.04M shares traded today
- Price Range: 52-week range of $3.81 - $5.70
- Exchange: Listed on NASDAQ Global Market
Financial Metrics
Market Analysis for Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. (VNDA) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 316.15M, the company represents a significant player in its market. The stock is currently trading at $5.35 with a positivedaily change of 21.59%.
The company's 368 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -3.72, beta of 0.71, and 52-week price range from $3.81 to $5.70when evaluating investment opportunities.
Why Invest in Vanda Pharmaceuticals Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Market)
- • Experienced leadership under Mihael H. Polymeropoulos
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.